COMT Inhibition for the Treatment of Parkinson's Disease: Articles

• COMT inhibitionA new treatment strategy for Parkinson's disease

  Matthias C. Kurth, Charles H. Adler

  • Abstract
  • Full Text
  • Full Text (PDF)
• Highlights of the North American and European experiences

  Christopher G. Goetz

  • Abstract
  • Full Text
  • Full Text (PDF)
• Levodopa therapyConsequences of the nonphysiologic replacement of dopamine

  Thomas N. Chase

  • Abstract
  • Full Text
  • Full Text (PDF)
• Influence of COMT inhibition on levodopa pharmacology and therapy

  Christopher G. Goetz

  • Abstract
  • Full Text
  • Full Text (PDF)
• Pharmacokinetics, pharmacodynamics, and tolerability of tolcaponeA review of early studies in volunteers

  Karin M. Jorga

  • Abstract
  • Full Text
  • Full Text (PDF)
• Tolcapone in stable Parkinson's diseaseEfficacy and safety of long-term treatment

  C. H. Waters, M. Kurth, P. Bailey, L. M. Shulman, P. LeWitt, E. Dorflinger, D. Deptula, S. Pedder, Tolcapone Stable Study Group

  • Abstract
  • Full Text
  • Full Text (PDF)
• Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

  H. Baas, A. G. Beiske, J. Ghika, M. Jackson, W. H. Oertel, W. Poewe, G. Ransmayr

  • Abstract
  • Full Text
  • Full Text (PDF)
• Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenonA double-blind, placebo-controlled, multicenter trial

  A. H. Rajput, W. Martin, M. H. Saint-Hilaire, E. Dorflinger, S. Pedder

  • Abstract
  • Full Text
  • Full Text (PDF)